Fudin, J. (2015, agosto). Monoclonal antibodies: How to navigate the naming scheme. Pharmacy Times Newsletter . Extraído de: http:// www.pharmacytimes.com/contributor/jeffrey-fudin/2015/08/ monoclonal-antibodies-how-to-navigate-the-naming-scheme Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J., Buqué, A., Senovilla, L., Baracco, E., . . . Kroemer, G. (2014). Classification of current anticancer immunotherapies. Oncotarget, 5 (24), 12472–12508. doi:10.18632/oncotarget.2998 Gobel, B. H. (2007). Hypersensitivity reactions to biologic drugs. Seminars in Oncology Nursing, 23 (3), 191–200. doi:10.1016/j. soncn.2007.05.009 Gottschalk, S., Rooney, C. M. e Brenner, M. K. (2016). Adoptive cellular immunotherapy. Em P. A. Pizzo e D. G. Poplack (Eds.), Principles and practice of pediatric oncology (7 a ed., pp. 384-401). Filadélfia, PA: Wolters Kluwer. Highlights of FDA Activities: 1/11/15–30/11/15. (2015, novembro). Washington State University Drug Information Center FDA Activity Newsletter . Disponível em https://pharmacy.wsu.edu/research/ druginfocenter/. Acesso em 9 de setembro de 2017. Kannan, R., Madden, K. e Andrews, S. (2014). Primer on immuno- oncology and immune response. Clinical Journal of Oncology Nursing, 18 (3), 311–317, 326. doi:10.1188/14.CJON.311-317 Kaushansky, K. (2006). Lineage-specific hematopoietic growth factors. New England Journal of Medicine, 354 (19), 2034–2045. doi:10.1056/ NEJMra052706 Khan, M. M. (2008). Role of cytokines. Em Immunopharmacology (pp. 33–59) (SpringerLink). doi:10.1007/978-0-387-77976-8 Kienle, P. C. (2017). The chapter <800> answer book. Bethesda, MD: ASHP Publications. King, J., Alexander, M., Byrne, J., MacMillan, K., Mollo, A., Kirsa, S. e Green, M. (2016). A review of the evidence for occupational exposure risks to novel anticancer agents: A focus on monoclonal antibodies. Journal of Oncology Pharmacy Practice, 22 (1), 121–134. doi:10.1177/1078155214550729 Kleibeuker, E. A., Ten Hooven, M. A., Castricum, K. C., Honeywell, R., Griffioen, A. W., Verheul, H. M., . . . Thijssen, V. L. (2015). Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Medicine, 4 (7), 1003–1015. doi:10.1002/cam4.441 Kolb, E. A. e Meshinchi, S. (2015). Acute myeloid leukemia in children and adolescents: Identification of new molecular targets bring promise of new therapies. Hematology: American Society of Hematology Education Program, 2015, 507–513. doi:10.1182/ asheducation-2015.1.507 Kreamer, K. M. (2014). Immune checkpoint blockade: A new paradigm in treating advanced cancer. Journal of the Advanced Practitioner in Oncology, 5 (6), 418–431. Lea, D. H. (2011). Gene therapy. Em C. H. Yarbro, D. Wujcik e B. H. Gobel (Eds.), Cancer nursing: Principles and practice (7 a ed., pp. 549-551). Sudbury, MA: Jones e Bartlett. Lemery, S. J., Ricci, M. S., Keegan, P., McKee, A. E. e Pazdur, R. (2016). FDA’s approach to regulating biosimilars. Clinical Cancer Research,
Maude, S. L., Barrett, D., Teachey, D. T. e Grupp, S. A. (2014). Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer Journal, 20 (2), 119–122. doi:10.1097/ PPO.0000000000000035 Mayer, G. (2016). Cytokines and immunoregulation. Em R.C. Hunt (Ed.), Microbiology and immunology on-line . Extraído de: www. microbiologybook.org/bowers/imm-reg-ver2.htm Muehlbauer, P. M. (2011). Cancer vaccines. Em C. H. Yarbro, D. Wujcik e B. H. Gobel (Eds.), Cancer nursing: Principles and practice (7 a ed., pp. 549-551). Sudbury, MA: Jones e Bartlett. National Cancer Institute. (2011). Angiogenesis inhibitors . Extraído de: https://www.cancer.gov/about-cancer/treatment/types/ immunotherapy/angiogenesis-inhibitors-fact-sheet National Cancer Institute. (2017). NCI-COG Pediatric MATCH . Extraído de: https://www.cancer.gov/about-cancer/treatment/clinical-trials/ nci-supported/pediatric-match National Cancer Institute. (2018). Targeted therapies. Extraído de: www.cancer.gov/about-cancer/treatment/types/targeted-therapies/ targeted-therapies-fact-sheet National Cancer Institute. (s.d.). Clinical trials database. Extraído de: https://clinicaltrials.gov/ct2/home National Institute for Occupational Safety and Health; Connor, T. H., MacKenzie, B. A., DeBord, D. G., Trout, D. B. e O’Callaghan, J. P. (2016). NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016 . DHHS (NIOSH) Publication Number 2016- 161 (substitui 2014-138). Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. National Institutes of Health, National Cancer Institute. (2016). Cancer vaccines . Extraído de: http://www.cancer.gov/about-cancer/ causes-prevention/vaccines-fact-sheet#q8 Packer, R. J., Pfister, S., Bouffet, E., Avery, R., Bandopadhayay, P., Bornhorst, M., . . . Kieran, M. (2017). Pediatric low-grade gliomas: Implications of the biologic era. Neuro Oncology, 19 (6), 750–761. doi:10.1093/neuonc/now209 Pennock, G. K. e Chow, L. Q. M. (2015). The evolving role of immune checkpoint inhibitors in cancer treatment. The Oncologist, 20, 812– 822. doi:10.1634/theoncologist.2014-0422 Pfizer, Inc. (2011). Neumega . Extraído de: https://www.pfizer.com/files/ products/uspi_neumega.pdf Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J. C., Kroemer, G. e Zitvogel, L. (2016). Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Annals of Oncology, 27 (8), 1482–1492. doi:10.1093/annonc/mdw168 Pollard, J. A., Loken, M., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Aplenc, R., . . . Meshinchi, S. (2016). CD33 expression and its association with gemtuzumab ozogamicin response: Results from the randomized phase III Children’s Oncology Group trial AAML0531. Journal of Clinical Oncology, 34 (7), 747–755. doi:10.1200/ JCO.2015.62.6846 Quail, D. F. e Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 19, 1423–1437. doi:10.1038/nm.3394 Ravandi, F. e Stone, R. (2017). Acute promyelocytic leukemia: A perspective. Clinical Lymphoma, Myeloma e Leukemia, 17 (9), 543– 544. doi:10.1016/j.clml.2017.06.037 Reeves, D. J., Quebe, A. K. e Patel, R. (2011). The ESA APPRISE oncology program: A history of REMS requirements, a review of the data, and an approach to compliance in the hospital. Pharmacy and Therapeutics, 36 (7), 423–433. Robinson, N. J., Campigotto, F., Chi, S. N., Manley, P. E., Turner, C. D., Zimmerman, M. A.,. . . Kieran, M. W. (2014). A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatric Blood and Cancer, 61 (4), 636–642. doi:10.1002/pbc.24794
23 (8), 1882–1885. doi:10.1158/1078-0432.CCR-16-1354 Lexi-Comp Online. (2017). Hudson, OH: Wolters Kluwer.
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., … Gruppo Italiano Malattie Ematologiche dell’Adulto, German-Austrian Acute Myeloid Leukemia Study Group, Study Alliance Leukemia. (2013). Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New England Journal of Medicine, 369 (2), 111–121. doi:10.1056/NEJMoa1300874 Mackall, C. L., Merchant, M. S. e Fry, T. J. (2014). Immune-based therapies for childhood cancer. Nature Reviews Clinical Oncology, 11, 693–703. doi:10.1038/nrclinonc.2014.177
148 Plano de Estudos de Quimioterapia e Bioterapia Pediátrica: Quarta Edição
Powered by FlippingBook